Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 1.1% – Should You Buy?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) traded up 1.1% on Tuesday . The company traded as high as $10.51 and last traded at $10.34. 446,289 shares traded hands during mid-day trading, a decline of 28% from the average session volume of 620,478 shares. The stock had previously closed at $10.23.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on FULC shares. Wall Street Zen lowered Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. HC Wainwright raised their target price on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Bank of America upped their price target on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a report on Tuesday, December 9th. Citigroup reissued an “underperform” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $23.00 price target (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.11.

Fulcrum Therapeutics Stock Performance

The stock has a market cap of $559.60 million, a P/E ratio of -8.76 and a beta of 3.19. The firm has a 50-day moving average price of $11.04 and a 200-day moving average price of $9.22.

Insider Transactions at Fulcrum Therapeutics

In related news, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $11.87, for a total transaction of $178,050.00. Following the sale, the director owned 469,864 shares of the company’s stock, valued at $5,577,285.68. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the completion of the sale, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 4,205,139 shares of company stock worth $58,711,943 over the last ninety days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Fulcrum Therapeutics

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $30,000. Quarry LP purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth $35,000. Farther Finance Advisors LLC increased its holdings in shares of Fulcrum Therapeutics by 108.3% during the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth about $100,000. Finally, Russell Investments Group Ltd. grew its position in Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after purchasing an additional 9,092 shares during the last quarter. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.